Carisma Therapeutics Inc. (CARM) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carisma Therapeutics Inc. (CARM) has a cash flow conversion efficiency ratio of -2.201x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.91 Million) by net assets ($-867.00K). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Carisma Therapeutics Inc. stock valuation for the company's overall valuation and market capitalisation.
Carisma Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Carisma Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carisma Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carisma Therapeutics Inc. ranked by their cash flow conversion efficiency. Explore Carisma Therapeutics Inc. cash earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
t42 IoT Tracking Solutions PLC
LSE:TRAC
|
-0.185x |
|
STRATA Skin Sciences Inc
NASDAQ:SSKN
|
-0.082x |
|
PHILION SE O.N.
F:PH6
|
N/A |
|
XLMedia PLC
LSE:XLM
|
-0.008x |
|
FAT Brands Inc
NASDAQ:FATBW
|
0.050x |
|
Chordate Medical Holding AB
ST:CMH
|
-0.514x |
|
Physiomics Plc
LSE:PYC
|
-0.514x |
|
Anemoi International Ltd
LSE:AMOI
|
-0.089x |
Annual Cash Flow Conversion Efficiency for Carisma Therapeutics Inc. (2011–2024)
The table below shows the annual cash flow conversion efficiency of Carisma Therapeutics Inc. from 2011 to 2024. View today's stock price for Carisma Therapeutics Inc. for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-27.91 Million | $-59.92 Million | 2.147x | +170.17% |
| 2023-12-31 | $26.53 Million | $-81.18 Million | -3.060x | -5869.38% |
| 2022-12-31 | $-142.67 Million | $-7.57 Million | 0.053x | +124.39% |
| 2021-12-31 | $171.71 Million | $-37.33 Million | -0.217x | -107.43% |
| 2020-12-31 | $-9.23 Million | $-27.01 Million | 2.927x | +108.32% |
| 2019-12-31 | $-26.70 Million | $-37.52 Million | 1.405x | +372.12% |
| 2018-12-31 | $44.21 Million | $-22.83 Million | -0.516x | +47.58% |
| 2017-12-31 | $18.03 Million | $-17.77 Million | -0.985x | -1553.09% |
| 2016-12-31 | $38.68 Million | $2.62 Million | 0.068x | +103.72% |
| 2015-12-31 | $18.94 Million | $-34.53 Million | -1.823x | -129.03% |
| 2014-12-31 | $36.83 Million | $-29.31 Million | -0.796x | +86.16% |
| 2013-12-31 | $2.35 Million | $-13.49 Million | -5.752x | -72.90% |
| 2012-12-31 | $5.74 Million | $-19.09 Million | -3.327x | -104.50% |
| 2011-12-31 | $-147.00K | $-10.87 Million | 73.939x | -- |
About Carisma Therapeutics Inc.
Carisma Therapeutics, Inc., a biotechnology company, focuses on developing transformative therapies to treat liver fibrosis and cancer in the United States. Its product candidates include CT-2401, which is in preclinical trial for the treatment of liver fibrosis. The company also develops CT-1119, a mesothelin-targeted CAR-Monocyte that is in phase I clinical trial to treat patients with advanced… Read more